Bioconjugate Experts Weigh in on Next-Generation ADC Characterization

A panel of bioconjugate analytical experts gathered to discuss next-generation antibody drug conjugate (ADC) characterization, sponsored by Waters Corporation.

The complexity of the bioconjugate landscape is growing, according to Colette Quinn, Senior Director and Portfolio Owner at Waters Corporation. She highlighted the increasing number of applications, including antibody-drug conjugates, antibody-oligonucleotide conjugates, and bioconjugate vaccines.

The panel consisted of Deanna Hunt, Senior Director of Business Development at KBI Biopharma; Lance Cadang, a scientist in Genentech's Synthetic Molecule Analytical Chemistry division; and Zhengqi Zhang, Associate Principal Scientist at Merck & Co. These experts joined the discussion to share their knowledge on next-generation ADC characterization.

The panelists explored the challenges and opportunities associated with the growing complexity of bioconjugates. They discussed various analytical techniques and strategies for characterizing these complex molecules.